Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Mirum Pharmaceuticals Inc
(NQ:
MIRM
)
41.12
+0.14 (+0.34%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Mirum Pharmaceuticals Inc
< Previous
1
2
3
4
5
6
7
8
9
Next >
Six-Year Natural History Comparison with Mirum’s LIVMARLI (maralixibat) Demonstrates Event-Free Survival and Transplant-Free Survival in Patients with Alagille Syndrome
November 15, 2021
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
The Week Ahead In Biotech (Nov. 14-Nov. 20): BioMarin FDA Decision, Tapering Earnings News Flow, Conference Presentations And More
November 14, 2021
Biotech stocks declined for the second straight week amid a broader market pullback, along with earnings news from small- and micro-cap companies and presentations at...
Via
Benzinga
Exposures
Product Safety
Expert Ratings For Mirum Pharmaceuticals
September 30, 2021
Mirum Pharmaceuticals (NASDAQ:MIRM) has observed the following analyst rat...
Via
Benzinga
The Daily Biotech Pulse: Merck Reports Positive Keytruda Readout, Moderna Slips Despite Q2 Beat, Bayer To Buy Vividion For Up To $2B, GlycoMimetics Gets New CEO
August 05, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 4) Absci, CORP (NASDAQ: ABSI) (...
Via
Benzinga
The Daily Biotech Pulse: Pfizer, Bristol-Myers Squibb Earnings, Amgen Goes Shopping, GlaxoSmithKline-Vir's COVID-19 Antibody Treatment Supply Deal
July 28, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 27) Bio-Rad Laboratories, Inc...
Via
Benzinga
Exposures
COVID-19
Earnings Scheduled For November 15, 2021
November 15, 2021
Companies Reporting Before The Bell • Sohu.com (NASDAQ:SOHU) is estimated to report earnings for its third quarter. • Tyson Foods (NYSE:TSN) is estimated to...
Via
Benzinga
Mirum Pharmaceuticals to Report Third Quarter 2021 Financial Results and Host Conference Call on November 15, 2021
November 08, 2021
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
New LIVMARLI™ (maralixibat) Data to be Showcased at AASLD The Liver Meeting® 2021
November 01, 2021
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
The Lancet Publishes Data From Mirum Pharmaceuticals' ICONIC Pivotal Study of Maralixibat (LIVMARLI) Treatment in Alagille Syndrome
November 01, 2021
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
10 Biggest Price Target Changes For Thursday
September 30, 2021
Jefferies raised Perrigo Company plc (NYSE:PRGO) pr...
Via
Benzinga
FDA Approves First Treatment For Alagille Syndrome-Associated Cholestatic Pruritus From Mirum Pharma
September 29, 2021
The FDA has approved Mirum Pharmaceuticals Inc (NASDAQ: MIRM) Livmarli (maralixibat) oral solution for cholestatic pruritus in patients with Alagille syndrome (...
Via
Benzinga
Exposures
Product Safety
12 Health Care Stocks Moving In Wednesday's After-Market Session
September 29, 2021
Gainers Regencell Bioscience (NASDAQ:RGC)...
Via
Benzinga
U.S. FDA Approves LIVMARLI (maralixibat) as the First and Only Approved Medication for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome One Year of Age and Older
September 29, 2021
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
The Daily Biotech Pulse: AbbVie's Migraine Drug OK'd By FDA, Amicus Spins Off Gene Therapy Business, Geovax In-Licenses Cancer Drug
September 29, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Click here for accessing Benzinga's FDA Calendar Scaling The Peaks (Biotech Stocks...
Via
Benzinga
Exposures
Product Safety
Mirum, Takeda Ink Maralixibat Licensing Pact In Japan
September 21, 2021
Mirum Pharmaceuticals Inc (NASDAQ: MIRM) and Takeda Pharmaceutical Company Limited (NYSE: TAK) have entered into an exclusive licensing agreement for...
Via
Benzinga
Mirum Pharmaceuticals and Takeda Enter into Exclusive Licensing Agreement to Develop and Commercialize Maralixibat for Rare Pediatric Liver Diseases in Japan
September 21, 2021
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
What 5 Analyst Ratings Have To Say About Mirum Pharmaceuticals
September 20, 2021
Within the last quarter, Mirum Pharmaceuticals (NASDAQ:MIRM) has observed ...
Via
Benzinga
Mirum Pharmaceuticals Submits European Marketing Authorization Application for Maralixibat in Alagille Syndrome Supported by New Positive Results from Natural History Study Comparison
September 13, 2021
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 10, 2021
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Mirum Pharmaceuticals to Participate in September Investor Conferences
September 02, 2021
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Attention Biotech Investors: Mark Your Calendar For September PDUFA Dates
August 31, 2021
August proved to be a mixed month for regulatory approvals, with the Food and Drug Administration approving a few, turning down a few others and delaying the remaining. New...
Via
Benzinga
Mirum Pharmaceuticals Appoints Biotechnology Executive William C. Fairey to its Board of Directors
August 19, 2021
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 10, 2021
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Mirum Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Business Update
August 05, 2021
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Mirum Pharmaceuticals to Report Second Quarter 2021 Financial Results and Host Conference Call on August 5, 2021
July 29, 2021
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Mirum Pharma Out-Licenses Maralixibat Rights To GC Pharma in South Korea
July 27, 2021
Mirum Pharmaceuticals Inc (NASDAQ: MIRM) and GC Pharma have entered into an exclusive licensing agreement to develop and commercialize Mirum's maralixibat...
Via
Benzinga
The Week Ahead In Biotech (Aug. 1-7): Biopharma Earnings Pick Up Pace, Eton Awaits FDA Decision, Focus On Pending Clinical Readouts and IPOs
August 01, 2021
Biotech stocks showed a lack of direction in the week ending July 30 amid earnings releases from big pharma companies. Most pharma majors reported strong quarterly results....
Via
Benzinga
Exposures
Product Safety
The Daily Biotech Pulse: Merck's Disappointing Q2, Atreca Falls On Data, FDA Nod For Viatris, Nuvalent, Icosavax IPOs
July 29, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 28) AbbVie Inc. (NYSE: ABBV)...
Via
Benzinga
Exposures
Product Safety
Stocks That Hit 52-Week Lows On Tuesday
July 27, 2021
During Tuesday's morning session, 216 companies made new 52-week lows. Noteworthy Points: Alibaba Group Holding (NYSE:BABA) was the largest firm by market cap...
Via
Benzinga
The Daily Biotech Pulse: ObsEva Surges On Out-Licensing Deal, EyeGate Appoints New CEO, 2 Positive Catalysts For Merck, Candel Therapeutics Debuts
July 27, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 26) Absci, CORP (NASDAQ: ABSI...
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.